Seeking Alpha

Delcath Systems announces more job cuts, with the company planning to reduce its U.S. workforce...

Delcath Systems announces more job cuts, with the company planning to reduce its U.S. workforce by 20% in order to concentrate on clinical development and the European commercialization of its Chemosat Hepatic Delivery System for administering the melphalan hydrochloride chemotherapy. As a result of this and other measures, Delcath expects cash utilization for Q4 to be $6-8M. The company also names senior company manager William Appling as Executive VP of R&D & Global Operations. Appling takes on the tasks of the departing Harold Mapes, who was responsible for ops. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector